A recombinant chimeric protein of protective antigen and lethal factor from Bacillus anthracis in polymeric nanocapsules showed a strong immune response in mice: a potential high efficacy vaccine against anthrax

Abstract

Anthrax is a serious infectious disease caused by Bacillus anthracis, rod-shaped gram-positive bacteria. The disease infects both humans and animals and causes severe illness. Many vaccines have been developed for anthrax, but the vaccine with very high efficacy is yet to be developed. To overcome the problems of efficacy posed by the existing vaccines, a recombinant chimeric fusion protein containing domain 1 of lethal factor (LFD1) and domain 4 of Bacillus anthracis protective antigen (PA4) was used as antigen in copolymeric nanocapsules (NCs). Accordingly, the solvent evaporation double emulsion method was used to produce NCs containing recombinant chimeric fusion protein (LFD1-PA4). Zeta sizer and potential of nanoparticles, nanoparticle loading efficiency, release pattern of recombinant protein, and the possible effect of polylactic acid-polyethylene glycol (PLA-PEG) nanoparticle production method were investigated. Mice were used to test and evaluate the immune response. The mean titer of antibody produced against loaded LFD1-PA4 compared to free form showed a significant difference. The difference in antibody titer between the groups of once injected, twice injected, and free antigen was significant, and the highest antibody titer was found in the mice twice injected. In addition, a single-time loaded injection showed significantly higher antibodies than the free form injection indicating that loaded LFD1-PA4 into PLA-PEG nanoparticles elicits a stronger immune response. This study showed that LFD1-PA4 fusion protein from Bacillus anthracis served as an active antigen in mice. Also, the nanocarrier (PLA-PEG) containing the antigen can stimulate the immune system in the mice, owing to their controlled release property.

Evaluating the effect of nurses' supportive and educational care on GATA2 gene expression and quality of life in patients with endometriosis

“…In many types of research, we have seen that at the end of the treatment, the social health of endometriosis patients was lower than at the beginning of the treatment period. Based on this, a minimal change or even a constant change in the quality of life score and especially the social health of patients is considered a success for researchers (33,34).…”

proteoglyThe role of different matrixin gene expressions on cerebral bleeding among patients with deficiency of coagulation factor XIII

“…Clinical studies show various complications and clinical signs in coagulation factor XIII deficiency patients (1,6,15,16). Preventive treatment compensates for the deficiency of coagulation factor XIII (in the form of replacing it with other products), preventing bleeding.…”

Harnessing Nanovaccines for Effective Immunization─A Special Concern on COVID-19: Facts, Fidelity, and Future Prospective

“…The prepared formulation has shown a high efficacy of vaccine for effective combat against anthrax. 122 3.2.5. Inorganic Nanoparticles.…”

“…Aziziaram et al studied the application of the recombinant chimeric protein containing protective antigen from Bacillus anthracis to induce a robust immune response in mice through polymeric nanocapsules formulations. The prepared formulation has shown a high efficacy of vaccine for effective combat against anthrax …”